Evidence map›Paper›PMID 31107982›Full record

ArticleEuropean journal of haematology2019

Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Tomoki Ito, Yoshinori Hashimoto, Yasuhiro Tanaka, Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Akiko Konishi, Masaaki Hotta, Hideaki Yoshimura and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.ORCID https://orcid.org/0000-0001-5419-9156
Yoshinori HashimotoDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.ORCID https://orcid.org/0000-0002-3374-9814
Yasuhiro TanakaDepartment of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Aya NakayaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.ORCID https://orcid.org/0000-0001-8365-3987
Shinya FujitaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Atsushi SatakeFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Takahisa NakanishiFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Akiko KonishiFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Masaaki HottaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Hideaki YoshimuraFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kazuyoshi IshiiFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Akiko HashimotoDepartment of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Toshinori KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Hiromi OmuraDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Isaku ShinzatoDepartment of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Takayuki TanakaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kansai Medical University · JPKobe City Nishi-Kobe Medical Center · JPTottori Prefectural Central Hospital · JPKawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy-naïve essential thrombocythemia (ET) patients in a real-world setting.

methodData from 53 ET patients who received anagrelide as a first-line therapy were reviewed for patient characteristics, antiplatelet status, cytoreduction status, therapeutic effects, adverse events, thrombohemorrhagic event development, progression to myelofibrosis or acute leukemia, and cause of death.

resultsThe rate of achieving a platelet count of <600 × 10

conclusionIn Japanese cytoreduction therapy-naïve ET patients, anagrelide administration as a first-line therapy demonstrated favorable effects in reducing platelet counts, and its safety profile that was generally consistent with those in previous reports.

Indexed as

AdultAgedAged, 80 and overBiomarkersDisease ProgressionDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMutationPlatelet Aggregation InhibitorsPlatelet CountQuinazolinesRisk FactorsThrombocythemia, EssentialanagrelideBiomarkersPlatelet Aggregation InhibitorsQuinazolinesanagrelideessential thrombocythemiafirst-linetreatment

Identifiers

PMID31107982
PMCPMC6851998
OpenAlexW2946743921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.